Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$301.85 USD

301.85
565,288

-3.17 (-1.04%)

Updated Jun 10, 2024 12:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Why Amgen (AMGN) Dipped More Than Broader Market Today

by Zacks Equity Research

Amgen (AMGN) closed the most recent trading day at $305.02, moving -0.22% from the previous trading session.

Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

by Zacks Equity Research

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates

by Zacks Equity Research

GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.

Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease

by Zacks Equity Research

Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.

Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report?

by Zacks Equity Research

Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: EverQuote, Micron, Amgen in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound

by Zacks Equity Research

Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.

The Zacks Analyst Blog Highlights Apple, Mastercard, Amgen, Utah Medical Products and Bridger Aerospace

by Zacks Equity Research

Apple, Mastercard, Amgen, Utah Medical Products and Bridger Aerospace are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Apple, Mastercard & Amgen

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA) and Amgen (AMGN), as well as two micro-cap stocks Utah Medical Products, Inc. (UTMD) and Bridger Aerospace Group Holdings, Inc. (BAER).

The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen

by Zacks Equity Research

Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.

Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC

by Zacks Equity Research

Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.

Sundeep Ganoria headshot

4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly

by Sundeep Ganoria

Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.

Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data

by Zacks Equity Research

Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?

by Zacks Equity Research

Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.

Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies

by Zacks Equity Research

Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.

Sanghamitra Saha headshot

4 Best ETF Areas of Last Week

by Sanghamitra Saha

Wall Street was upbeat last week with the S&P 500 adding 1.9%, the Dow Jones advancing 2.2% and the Nasdaq Composite gained 1.1%.

Sanghamitra Saha headshot

Best Inverse/Leveraged ETFs of Last Week

by Sanghamitra Saha

Wall Street was upbeat last week. Notably, on Friday, the Dow secured its eighth consecutive session of gains.

The Zacks Analyst Blog Highlights Amgen, Amazon.com, Apple, Boeing and Goldman Sachs

by Zacks Equity Research

Amgen, Amazon.com, Apple, Boeing and Goldman Sachs are included in this Analyst Blog.

Sweta Killa headshot

5 Stocks Driving Dow's Market-Beating Performance

by Sweta Killa

Dow Jones outperforms at the start of May as the market rally broadens and reconstruction of the index finally pays off.